Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: CT-388, RO7795068, RG6640
Enicepatide is a synthetic, lipidated peptide investigational compound developed as a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It was designed to produce cAMP-biased signaling with minimal beta-arrestin recruitment and reduced receptor internalization in experimental systems. Clinical development has evaluated subcutaneous administration in obesity, overweight with weight-related comorbidity, and type 2 diabetes. It is not an approved medicine.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Research regimens reported in primary sources include phase 1 single subcutaneous doses of 0.5–7.5 mg and four once-weekly subcutaneous doses of 5–12 mg. A phase 2 obesity study evaluated once-weekly subcutaneous dosing with titration schemes reaching 24 mg over 48 weeks. A separate phase 2 study in participants with type 2 diabetes and overweight or obesity evaluated once-weekly subcutaneous administration for 48 weeks, with titration up to 24 mg. These are study regimens reported for scientific reference and are not dosing recommendations.
Supplementary research context only. Not medical advice or a treatment recommendation.
Proposed INN: enicepatide; CAS RN: 2869147-44-2; molecular formula: C226H345FN48O67; development codes: CT-388, RO7795068, RG6640.
The WHO Proposed INN record classifies enicepatide as a dual GIP and GLP-1 receptor agonist and provides the peptide's chemical description, molecular formula, and CAS Registry Number. ClinicalTrials.gov identifies CT-388, RO7795068, and RG6640 as alternative names for enicepatide. Current sources describe the compound as investigational and in late-stage clinical development.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention enicepatide or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.